Non-Opioid Pain Drug Developer Soars Over 14% in Market Debut
Stock News
Aug 08
On Friday, Latigo Biotherapeutics (LTGO.US) made its public market debut, with shares surging more than 14% to $20.53 at the time of writing.
The company is a developer of non-opioid pain medications targeting the Nav1.8 sodium channel. Its lead candidate, LTG-001, is an oral Nav1.8 inhibitor designed to treat moderate-to-severe acute pain, including postoperative pain.
This drug aims to deliver analgesic effects comparable to opioids while eliminating the risk of addiction. Since Nav1.8 is primarily expressed in peripheral pain-sensing neurons and does not act on the central nervous system, its inhibitors are not addictive.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.